Some hospitals in the Greater Bay Area in China may exempt from the China NMPA registration for use the drug and medical devices registered in Hong Kong SAR

In the meeting that the Chief Executive of the Government Hong Kong Special Administrative region, Mrs Carrie Lam attended in Beijing on Nov 6th, 2019, 16 policy measures are introduced to offer further convenience to Hongkonger developing their careers, working and living in the Mainland cities of the Greater Bay Area (Guangdong-Hong Kong-Macau-Greater Bay area, including Guangzhou, Shenzhen, Zhuhai, Foshan, Dongguan, Zhongshan, Jiangmen, Huizhou, and Zhaoqing, as well as Hong Kong and Macau.).

In one of the policy measures, it is said that the Central Government has accepted a proposal from the HKSAR Government to permit the use of Hong Kong-registered drugs and common medical devices in designated Hong Kong-owned healthcare institutions in the Greater Bay Area. The Food and Health Bureau will be in discussion with relevant Mainland authorities on the implementation details, including implementing the measure at the University of Hong Kong-Shenzhen Hospital on a pilot basis.

This means that the products may enter Chinese market without the long registration process of NMPA in those Hong Kong-owned healthcare institutions, but only a much shorter registration process at the Hong Kong authority.

Once the implementation details are settled, it would be a very great news for overseas pharmaceutical and medical device companies to enter Chinese market.

JMedTec is an expert team with lots experiences for medical device and drugs registration in both China and Hong Kong SAR. Please feel free to contact us for registering your product in Hong Kong SAR.